about
Icosapent ethyl for the treatment of severe hypertriglyceridemia.From Inuit to implementation: omega-3 fatty acids come of age.Added fructose: a principal driver of type 2 diabetes mellitus and its consequences.Combination drug therapy for dyslipidemia.Autonomic tone as a cardiovascular risk factor: the dangers of chronic fight or flight.Strategies for optimizing glycemic control and cardiovascular prognosis in patients with type 2 diabetes mellitus.Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer.Omega-3 fatty acids for cardioprotection.Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?Prevalence of vitamin D deficiency in patients with acute myocardial infarction.Psychosocial stress and cardiovascular disease: how to heal a broken heart.Strategies to prevent type 2 diabetes.Behavioral cardiology: recognizing and addressing the profound impact of psychosocial stress on cardiovascular health.The rationale and indications for angiotensin receptor blockers in heart failure.Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor.Postprandial dysmetabolism: the missing link between diabetes and cardiovascular events?The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection.A longer course of varenicline therapy improves smoking cessation rates.Cardiac physical diagnosis in the digital age: an important but increasingly neglected skill (from stethoscopes to microchips).Statins as anti-arrhythmics: a systematic review part II: effects on risk of ventricular arrhythmias.Statins as antiarrhythmics: a systematic review part I: effects on risk of atrial fibrillation.Achieving hunter-gatherer fitness in the 21(st) century: back to the future.Impact of exercise training on psychological risk factors.Psychological risk factors and cardiovascular disease: is it all in your head?Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Coffee and tea: perks for health and longevity?Triple versus dual antiplatelet therapy in acute coronary syndromes: adding cilostazol to aspirin and clopidogrel?Exercise and the heart--the harm of too little and too much.Insights into the pathogenesis and prevention of coronary artery disease.Influence of left ventricular mass on coronary artery cross-sectional area.Can vitamin D deficiency break your heart?ST-segment elevation: defined by the company it keeps.Boosting endogenous production of vasoprotective hydrogen sulfide via supplementation with taurine and N-acetylcysteine: a novel way to promote cardiovascular health.Targeting aspirin resistance with nutraceuticals: a possible strategy for reducing cardiovascular morbidity and mortality.Perindopril for improving cardiovascular events.Neutralizing the adverse prognosis of coronary artery calcium.Of mice and men: atrial fibrillation in veteran endurance runners.Niacin therapy lives for another day-maybe?Exercising for health and longevity vs peak performance: different regimens for different goals.Dose of jogging and long-term mortality: the Copenhagen City Heart Study.
P50
Q27686834-B055531F-B49A-4CD1-B4E3-2280959D4AB9Q33942206-C0C57908-6D15-40E6-B569-70908839FEC0Q34043079-862AE27F-89C9-4C1C-9FE5-C48417E14523Q34107165-1ACABF0C-B406-4DA3-9A2C-3A5C00AA61E6Q34496201-4216E780-76DB-44FE-92A3-196A8F839A41Q34541875-3D48E81A-E05F-4660-8110-CCFBD6775953Q34544366-14BF76A1-5D76-433B-8AE5-0B504B06EA96Q34588995-9EAE5BBD-C9B0-4989-ACA1-18B6EA86A54AQ34894926-CC707BA8-4946-4F20-BA78-EBE614F72C5EQ35060685-F6136C9F-10BC-45F7-8413-0225020FE070Q35783514-C5A2420D-FE13-418C-BFE2-D3D9D0669ADBQ36187164-CE0AF3FC-521A-43D2-B326-6378C6CA241AQ36410596-9BFE5B6D-2365-419C-8B25-8C4E4DC66D09Q36770885-82F6D493-5F64-4012-AA48-5A3489EFCC46Q36919077-08A71160-34AB-4B56-B4FC-19CAC8A6F835Q37073157-A2330200-06BA-4002-AE24-1444A3062ED8Q37169716-E001A373-882E-406E-BA8D-5B73D8A51ACBQ37499007-F08F0065-9F97-4408-9BFA-68623ACC1D42Q37574356-290A59E6-B0C9-433A-947E-F3656855C993Q37611724-068D118D-1B64-46EE-AD82-2ED4867CBC2DQ37632310-7B447F25-5A44-4E85-BEA6-4F4F83903123Q37789069-02A80362-51A4-493C-9AF1-597A599B5FBDQ37872425-06ACA8EB-5FE3-43AF-8466-8478E22211AAQ37929507-7B87CBB0-6DC0-4168-929C-07BC8E98AB9FQ38128175-17FF5891-9526-4404-B1A6-F91E69E75620Q38144708-2F440C00-9D84-407E-A6D1-C1102216E108Q38150944-AA4E8468-20CD-4CBB-A544-1D183EEAF858Q38372080-113C5DFB-9108-4DA7-8D07-8EDD225CF439Q40561201-B75316FA-62F3-4A55-99AB-E4CCC2A75187Q41355578-9D84ADA2-ABC2-4E3B-9987-F26B2083CACDQ42335505-2572184B-417C-475E-9056-2880EE9D505CQ42335821-4DA96981-9BFE-423C-9BC0-EC4F4549074BQ42338456-1536AAA8-C0F0-4584-B095-AC38C71FAA3CQ42355197-16A46595-45D7-4BE3-B338-149834F61380Q42864618-3FAD62D2-94E6-4E96-AA7C-BE7D83685D84Q43637260-71ABAAAD-E694-484E-8BA3-E5F0C5249CD9Q44297115-39317DD1-7B49-46DE-9D97-BF2518765E8CQ44361174-FB628187-2102-4D9D-8230-F7F4E20510EFQ44627020-2ADF7AB8-0715-4D9C-A355-78C85F8786DAQ44962324-73587F2C-BB81-451B-AA79-A7732A020A58
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
James H O'Keefe
@ast
James H O'Keefe
@en
James H O'Keefe
@es
James H O'Keefe
@nl
James H O'Keefe
@sl
type
label
James H O'Keefe
@ast
James H O'Keefe
@en
James H O'Keefe
@es
James H O'Keefe
@nl
James H O'Keefe
@sl
prefLabel
James H O'Keefe
@ast
James H O'Keefe
@en
James H O'Keefe
@es
James H O'Keefe
@nl
James H O'Keefe
@sl
P106
P21
P31
P496
0000-0002-3376-5822